CONCLUSION
The study findings illustrate a higher bioavailability of the developed
10 mg/mL oral suspension dosage form compared to the 50mg tablet and
exemplify that not all liquid 6-MP formulations are equal in terms of
bioavailability of the parent drug. A starting dose 20% lower than the
tablet formulation is proposed based on model informed dose
optimization. Switching to PFOS can minimize sub-therapeutic or toxic
exposures. However, dose modifications should be anticipated to maintain
treatment intensity with close monitoring of the patient for blood
counts and liver enzymes. The simulated exposures of 6MP according to
the adjusted dosage regimens recommended model must be validated in
real-time clinical conditions.